Henry Chambers

Henry Chambers is a Professor of Medicine and has been a faculty member at the University of California, San Francisco (UCSF) since 1983. He serves as the Chief of the Division of Infectious Diseases at San Francisco General Hospital (SFGH) and the Director of Clinical Research Services for the Clinical and Translational Science Institute (CTSI). His research and clinical interests focus on antimicrobial drug resistance, staphylococcal infections, and the epidemiology of Staphylococcus aureus. He has over 200 publications and textbook chapters, and edits the Sanford Guide to Antimicrobial Therapy. Dr. Chambers received his BA from Centre College, his MD from Vanderbilt University School of Medicine, and trained in Internal Medicine and Infectious Diseases at UCSF.

Education:

• BA, Centre College, Kentucky
• MD, Vanderbilt University School of Medicine
• Internal Medicine and Infectious Diseases Training, UCSF

His research spans antimicrobial resistance mechanisms, bacterial pathogenesis, and translational therapeutics. Key areas include β-lactam resistance in MRSA, the role of sodium bicarbonate in antibiotic efficacy, and the molecular epidemiology of resistant pathogens like carbapenemase-producing Enterobacteriaceae. He leads grants funded by NIH, focusing on projects such as the Antibacterial Resistance Leadership Group (ARLG) and mechanisms of Staphylococcal resistance.

His lab's work bridges basic science and clinical practice, contributing to antibiotic development and treatment guidelines. He collaborates on large-scale initiatives like the ARLG, which addresses antimicrobial resistance through clinical trials and epidemiological studies. His contributions to the field include advancements in understanding MRSA resistance and optimizing antibiotic therapies for complex infections.

Notable grants include the NIH-funded ARLG (UM1AI104681) and studies on β-lactam resistance mechanisms (R01AI100291). His publications emphasize antibiotic efficacy, resistance mechanisms, and improving clinical outcomes in severe infections like endocarditis and bacteremia.